ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Trading 2.4% Higher – Here’s Why

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO)’s stock price traded up 2.4% during trading on Thursday . The company traded as high as $65.01 and last traded at $64.90. 49,921 shares changed hands during trading, an increase of 40% from the average session volume of 35,636 shares. The stock had previously closed at $63.35.

ALPS Medical Breakthroughs ETF Price Performance

The firm’s 50-day simple moving average is $55.08 and its two-hundred day simple moving average is $52.82.

Institutional Trading of ALPS Medical Breakthroughs ETF

Hedge funds and other institutional investors have recently modified their holdings of the stock. Exencial Wealth Advisors LLC raised its position in ALPS Medical Breakthroughs ETF by 3.2% in the 4th quarter. Exencial Wealth Advisors LLC now owns 8,101 shares of the company’s stock worth $415,000 after purchasing an additional 248 shares during the last quarter. Royal Bank of Canada boosted its position in ALPS Medical Breakthroughs ETF by 2.8% in the 4th quarter. Royal Bank of Canada now owns 12,269 shares of the company’s stock valued at $628,000 after buying an additional 330 shares during the last quarter. McGuire Investment Group LLC increased its stake in shares of ALPS Medical Breakthroughs ETF by 5.9% in the 4th quarter. McGuire Investment Group LLC now owns 8,798 shares of the company’s stock valued at $451,000 after buying an additional 488 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in shares of ALPS Medical Breakthroughs ETF in the 4th quarter valued at $26,000. Finally, Griffin Asset Management Inc. raised its position in shares of ALPS Medical Breakthroughs ETF by 1.9% during the fourth quarter. Griffin Asset Management Inc. now owns 30,699 shares of the company’s stock worth $1,572,000 after acquiring an additional 564 shares during the last quarter.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.